A Pilot Study to Evaluate the Role of High-dose Ranibizumab (2.0mg) in the Management of AMD in Patients With Persistent/Recurrent Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy (the LAST Study)

NCT01115556 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Age Related Macular Degeneration

Interventions

DRUG: Ranibizumab
DRUG: Ranibizumab

Sponsor

Vitreous -Retina- Macula Consultants of New York

Collaborators

[object Object]